胰腺癌：KOL 的观点

本报告分析了全球胰腺癌 (PC) 治疗药物市场的概况，包括疾病概况、主要治疗方法、概况 我们将汇总并发布 KOL（行业专家）的意见等信息市场走向。

内容

执行摘要

胰腺癌 (PC) 当前和未来的治疗方案

研究目的

批准的药物

• 免疫疗法
  • Keytruda（pembrolizumab，默克公司）
  • Lynparza（奥拉帕尼，阿斯利康）

后期管线药物

• 多胺抑製剂
  • Ivospemin（SBP101，Panbela Therapeutics）
• 结缔组织生长因子 (CTGF) 抑製剂
  • Pamrevlumab（FibroGen）
• 其他新药
  • 马赛替尼（AB Science）
  • GRASPA（Eryaspase，Erytech Pharma）

早期管线药物 - 抗 PD-1/PD-L1 联合疗法

• Jemperli（dostarlimab，GSK）和 Zejula（niraparib，GSK）
  • 关键见解总结
• Opdivo（nivolumab，Bristol Myers Squibb）和联合疗法
• PD-L1 t-haNK (ImmunityBio)□Anktiva (ImmunityBio)
• Letifanlimab（因塞特）Erragussib（9-ING-41，Actuate Therapeutics）

早期管道药物 - 其他新兴疗法

• Tedopi（OSE 2101，OSE 免疫疗法）
  • 关键见解总结
• NIS793□Spartalizumab（诺华）
• Nadunolimab（CAN-04，Cantargia）
• Mitazalimab（Alligator Bioscience）□CDX 1140（Celldex Therapeutics）
• AZD 0171（阿斯利康）
• ABTL 0812（能力製药）
• Omvansertib（卡迪夫肿瘤科）
• Tem Telquib（礼来公司）

胰腺癌 (PC) 药物的未来趋势和机会

• 最终与临床相关的 PC 免疫检查点抑製剂：不太可能在未来 3-5 年内实现，但研究人员继续从各个角度进行实验
  • 在可预见的未来，化疗仍然是 PC 治疗的基石，但随着免疫疗法和新型药物的结合，情况可能会发生变化

附录

• KOL 详情
  • 北美的 KOL
  • 欧洲 KOL

While Merck & Co's Keytruda is seen as a 'game changer' for US patients with unresectable or metastatic microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) solid tumours, or tumours that have high mutational burden (TMB-high), do KOLs see its potential in larger PC populations? Will Phase III POLO study readouts impact the use of Lynparza? How do KOLs assess the potential of FibroGen's pipeline CTGF inhibitor pamrevlumab? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the KOL Bulletins via the Attachments area

Table of Contents

Executive summary

Current and future treatment algorithm for PC

Research objectives

Approved drugs

• Immunotherapy
  • Keytruda (pembrolizumab; Merck & Co.)
  • Lynparza (olaparib; AstraZeneca)

Late-stage pipeline drugs

• Polyamine inhibitors
  • Ivospemin (SBP101; Panbela Therapeutics)
• Connective tissue growth factor (CTGF) inhibitors
  • Pamrevlumab (FibroGen)
• Other novel agents
  • Masitinib (AB Science)
  • GRASPA (eryaspase; Erytech Pharma)

Early-stage pipeline drugs - anti-PD-1/PD-L1 combinations

• Jemperli (dostarlimab; GSK) and Zejula (niraparib; GSK)
  • Key insights summary
  • Opdivo (nivolumab; Bristol Myers Squibb) and combinations
  • PD-L1 t-haNK (ImmunityBio) and Anktiva (ImmunityBio)
  • Retifanlimab (Incyte) and elraglusib (9-ING-41; Actuate Therapeutics)

Early-stage pipeline drugs - other novel therapies

• Tedopi (OSE 2101; OSE Immunotherapeutics)
  • Key insights summary
  • NIS793 and spartalizumab (Novartis)
  • Nadunolimab (CAN-04; Cantargia)
  • Mitazalimab (Alligator Bioscience) and CDX 1140 (Celldex Therapeutics)
  • AZD 0171 (AstraZeneca)
  • ABTL 0812 (Ability Pharmaceuticals)
  • Onvansertib (Cardiff Oncology)
  • Temuterkib (Eli Lilly)

Future trends and opportunities in PC treatment

• The holy grail of clinically meaningful efficacy of immune checkpoint inhibitors in PC may not be achievable within the next three to five years, but investigators continue to try all angles
  • Chemotherapy will remain the cornerstone of treatment in PC for the foreseeable future, but with increasing integration of immunotherapy and novel agents

Appendix

• KOL details
  • KOLs from North America
  • KOLs from Europe